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Abstract
Background: Low back pain (LBP), with high incidence and prevalence rate, is one of the most common reasons
to consult the health system and is responsible for a significant amount of sick leave, leading to high health and
social costs. The objective of the study is to assess the cost-effectiveness and cost-utility analysis of a
multidisciplinary biopsychosocial educational group intervention (MBEGI) of non-specific sub-acute LBP in
comparison with the usual care in the working population recruited in primary healthcare centres.
Methods/design: The study design is a cost-effectiveness and cost-utility analysis of a MBEGI in comparison with
the usual care of non-specific sub-acute LBP.
Measures on effectiveness and costs of both interventions will be obtained from a cluster randomised controlled
clinical trial carried out in 38 Catalan primary health care centres, enrolling 932 patients between 18 and 65 years
old with a diagnosis of non-specific sub-acute LBP. Effectiveness measures are: pharmaceutical treatments, work
sick leave (% and duration in days), Roland Morris disability, McGill pain intensity, Fear Avoidance Beliefs (FAB) and
Golberg Questionnaires. Utility measures will be calculated from the SF-12. The analysis will be performed from a
social perspective. The temporal horizon is at 3 months (change to chronic LBP) and 12 months (evaluate the
outcomes at long term).
Assessment of outcomes will be blinded and will follow the intention-to-treat principle.
Discussion: We hope to demonstrate the cost-effectiveness and cost-utility of MBEGI, see an improvement in the
patients’ quality of life, achieve a reduction in the duration of episodes and the chronicity of non-specific low back
pain, and be able to report a decrease in the social costs. If the intervention is cost-effectiveness and cost-utility, it
could be applied to Primary Health Care Centres.
Trial registration: ISRCTN: ISRCTN58719694
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Background
Lower back pain (LBP), in any of its forms (acute, suba-
cute, chronic), is one of the principal reasons for consult-
ing the general practitioner (GP). The annual prevalence
of LBP is estimated at 14.8% in a study carried out in the
Spanish population [1], and these results were confirmed
by the 2006 Spanish National health survey [2] and
recent data from the Primary Care Information System of
Catalonia [3].
LBP has an important impact in the performance of
daily tasks and the quality of life of the individuals
affected by this pathology. It also has social and family
repercussions which are often ignored [1,4]. LBP is one
of the six most frequent health problems in developed
countries [5,6]. When the LBP diagnosis is established,
the minimisation of disability and the cost of labour
absenteeism constitutes a shared problem among
patients, health professionals, business management, and
administration, and makes early intervention necessary
to avoid chronic LBP. Some epidemiological studies
show that aspects such as psychosocial malaise and fear
and avoidance behaviour are associated with a higher
risk of developing incapacity in the long term. In
patients with these characteristics, a cognitive beha-
vioural intervention has been shown to be effective in
reducing this risk [7,8]. Therefore, psychological and
social factors associated with the symptoms should be
considered because they could affect the level of pain
and increase the risk of evolution to chronic LBP [9-12].
Failure to reduce pain represents an important increase
in the economic cost to society and reduction in the
quality of life of the patient [13,14].
The labour absenteeism caused by LBP is estimated at
an average of 21.9 working days lost per illness episode,
which represents a cost of 1260 € per worker per year [3].
This cost would be higher if the calculation also took into
account “presenteeism” (reduced work productivity),
which doubles or triples the cost of labour absenteeism
alone [15]. Clinical practice guidelines include scant infor-
mation about the cost-effectiveness of the treatments,
except for those provided by the National Institute for
Health and Clinical Excellence (NICE) [16]. In addition,
the few studies published have important methodological
limitations and are very heterogeneous, which limits the
available evidence about the cost effectiveness of LBP
interventions [17,18].
Given that the guidelines considered a range of interven-
tions to be effective, it is important to assess the efficiency
of treatments versus current intervention throughout the
cost-effectiveness analysis [19-21]. As the number of pub-
lished economic evaluations of interventions for LBP is
increasing, it may now be possible to consider evidence of
cost-effectiveness when making recommendations about
treatment [15,22]. However, no studies have been identi-
fied that analyse the cost-effectiveness and cost-utility of
multidisciplinary biopsychosocial interventions with
respect to habitual practice in primary care.
The objective of the study is to assess from a societal
perspective the cost-effectiveness and cost-utility of a
multidisciplinary biopsychosocial educational group
intervention (MBEGI) in comparison with the usual care
of non-specific sub-acute LBP in the working population
recruited in Barcelona and its surrounding Primary
Health Care Centres (PHCC) since May 2009.
Secondary objectives are to identify and quantify the
various costs associated with the disease and their distri-
bution among all of the actors in society.
Methods/Design
Study design
Cost-effectiveness and cost-utility analysis of a cluster
randomised clinical trial which compares patients with
subacute non-specific LBP treated with a MBEGI
approach, with a control group receiving only usual clini-
cal care in PHCC. The analysis adopts the societal per-
spective because, it takes into consideration all other
perspectives, will provide disaggregated data, and will
make available the most extensive information for use in
comparing studies [23].
Setting (*)
The trial is being conducted in a primary care setting, in
38 PHCCs located in Barcelona, Spain and its surround-
ing areas. We contact all the PHCCs, present the study
to their staff members and invite them to participate.
Study population
Eligible patients will be identified by the GP or nurses
when they consult for a new episode of sub-acute LBP or
from searches of electronic clinical records. Patients are
informed about the study objectives and those who agree
to participate will be given written informed consent to
sign.
Patients will be included if the current episode of LBP
occurs suddenly after at least 6 months without LBP
and lasts between 15 days and 12 weeks [24], and if
they do not fulfil any of the exclusion criteria [20].
Furthermore, patients must be between 18 and 65
years old, understand Catalan or Spanish, and be avail-
able to participate for at least 12 months. Patients will
be excluded if: (a) they are unwilling to participate in
the multidisciplinary intervention trial; (b) LBP coexists
with cognitive impairment, severe psychiatric disorders
such as psychosis, or severe major depression; (c) any
other cause of disability impedes answering the various
questionnaires; (d) they are pregnant or breast-feeding;
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(e) they might have anti-inflammatory intolerance or
allergy; (f) treatment has been received for physical pro-
blems in the preceding 3 months; (g) they have been
referred for intensive functional restoration pro-
grammes; or (h) they have a confirmed diagnosis of
fibromyalgia.
Furthermore, the GP has to ensure that the patient
has no red flag signs or symptoms that are frequently
associated with specific LBP or potentially severe ill-
nesses [25-28].
Randomisation
In this study a cluster design is used because the interven-
tion is delivered to groups. To minimise contamination,
the unit of randomisation will be the PHCC. Those
PHCCs who agree to participate will be randomly allocated
to control or intervention groups by a random sequence
generated by a computer programme in blocks of random
size and prepared before recruitment of the PHCC by an
independent statistician who will be blinded to the PHCC
identity. The blocking factor was a randomly selected even
number (i.e., 4, 6, or 8) and will vary as the recruitment
continues. GP or nurses will be informed about their allo-
cation after giving final consent to participation.
To minimise imbalance across intervention groups, ran-
domisation was stratified by percentage of immigrants
from developing countries registered in each district. We
consider two strata, less than and more than 15% immi-
grants. This variable is taken as a proxy of socioeconomic
level.
Blinding
During the recruitment, patients who meet the inclusion
criteria are allocated to the intervention group corre-
sponding to the centre. To avoid bias, consent to partici-
pate is obtained before the allocation. Because of the
nature of the intervention, GPs or nurses cannot be blind
to patients’ allocation. Data analysis will be carried out so
that the intervention groups allocated to the patients will
be unknown to the analyst.
Intervention Design
Control group
Patients allocated to the control group will receive usual
clinical care, and individual intervention based on the
application of the “Clinical Practice Guidelines in the
Pathology of the Lumbar Spine in Adults”. These
recommendations are published by the Catalan Institute
of Health (Institut Català de la Salut) [25]. Details are
given in Table 1.
Intervention group
In addition to the same individual intervention as the
control group, patients allocated to the intervention
group will receive an educational booklet “The Back
Manual” [29] (a transculturally adapted Spanish version
of the Back Book) [30] and a biopsychosocial multidisci-
plinary group intervention.
The group intervention will be carried out by a GP, a
nurse, a psychologist and a physiotherapist. The pro-
gramme consists of 2 sessions of 4 hours duration each
and 1 session of 2 hours duration. Each group includes
up to 12 participants. Details of the MBEGI intervention
and the educational digital video disc (DVD) are
included in Tables 2 and 3.
To guarantee the standardisation of the group sessions,
only one qualified psychologist and one physiotherapist,
both of them with extensive expertise in development of
training groups, will apply the intervention in all PHCCs.
Outcomes
Effectiveness measures The primary effectiveness mea-
sures of the study consist of Roland Morris Disability
Questionnaire (RDQ) [31,32] (scale 0-24; lower score
indicates lower disability), Mc Gill Pain Questionnaire
[33-37] (including VAS 1-10; lower score indicates less
pain), and Goldberg questionnaire on anxiety and
depression. Duration of days of pain, the reduction of
days off work, the reduction of prescription, the dura-
tion of pharmacological treatments and recurrent epi-
sodes of LBP and the incidence of chronic LBP at 12
months will be measured.
The secondary effectiveness measures are inadequate
behaviour and work factors assessed by Fear Avoidance
Beliefs Questionnaire (FAB) [38] (scale 0-24; lower score
indicates lower fear-avoidance belief), and the Goldberg
questionnaire of anxiety and depression [39] (each scale 0-
9; lower scores indicates less anxiety or depression). All
these questionnaires are validated in Spanish. Patient’s
assessment of global perceived effect on health will be mea-
sured by self-assessment with a Likert 7-point scale [40].
Table 1 Contents of the clinical guidelines applied in the
cluster randomised trial
Clinical Practice Guidelines in the Pathology of the Lumbar Spine
in Adults
■ Patient education, give reassuring and positive information about the
benign nature of LBP, offer written information including specific
advice.
■ Advise avoiding bed-rest and encourage the person to be physically
active and continue with normal activities as far as possible.
■ Consider offering a structured physical exercise program tailored to
personal preferences
■ Physical exercise should be introduced gently at first (walking, cycling,
and swimming) and progressively increased in intensity.
■ Recommend attendance at the “Back School” to those patients who
have not resumed their daily tasks, after six weeks.
■ Prescribe pharmacological treatment according to the established
guidelines
Notes: LBP = low back pain.
Berenguera et al. BMC Musculoskeletal Disorders 2011, 12:194
http://www.biomedcentral.com/1471-2474/12/194
Page 3 of 9
Utility measures The primary utility measure of the
study is quality adjusted life years (QALYs), and will be
calculated from the SF-12 scores (scale 0-100; lower
score indicates poorer quality of life) [32].
Other variables The main independent variable is the
intervention arm: MBEGI, or usual clinical care.
Sociodemographic and clinical variables were detailed
in the study protocol [21]. Among others, clinical
variables are PHCC and hospital emergency visits due to
current sub-acute LBP episode; patient compliance with
recommendations and treatments; prescribed diagnostic
tests; prescribed pharmacological treatment; referrals to
other departments; and nonpharmacological treatment
measures [41]. Absenteeism will be calculated, and
reduced work productivity (presenteeism) will be mea-
sured by the Quantity and Quality instrument (QQ).
The amount and quality of productivity will be mea-
sured on a 10-point numerical rating scale, with 0 repre-
senting “nothing” and “very poor quality,” respectively,
and 10 representing “normal quantity” and “normal
quality,” respectively [42,43].
Other non-pharmacological therapeutic measures and
Patient Compliance The non-pharmacological thera-
peutic measures are detailed in Table 4.
During follow-up visits (at 3, 6 and 12 months) we
will ask the patient about compliance with treatment
recommendations and data collection questionnaires
will be completed.
Measures of resources and costs The costs analysis will
be conducted using a bottom-up approach (bottom-indi-
vidual; up-societal costs). Average costs will be calculated
for each particular type of cost. Costs related to both the
MBEGI and the usual care will be collected. The costs of
non-specific sub-acute LBP and its treatment consist of
direct medical costs and direct and indirect non-medical
costs [44]. An overview of the measured costs and the
corresponding sources can be found in table 4.
Direct medical costs include those attributable to
health care visits for the treatment of LBP: the cost of
MBEGI material utilized and distributed to the
patients; visits to primary care professionals, to other
specialists, and to rehabilitation services; number of
Table 2 Components of the biopsychosocial
multidisciplinary group intervention
GP + Nurse
2 hours
Objective: Resolve doubts, demystify concepts
about LBP and promote adherence to the
intervention
■ Basics on anatomy and biomechanics of the spine
■ Pain mechanisms
Theory program ■ Causes of pain and predisposing factors
■ Type of pain, mechanical, inflammatory, and
severity
■ Healthy life habits
Practical
program
■ Discuss with the participants the doubts, beliefs
and myths about back pain and give positive
messages
Physiotherapist
4 hours
Objective: Provide tools on exercises/postures to
avoid the pain and the chronic course and
improve quality of life.
■ Body posture and its implication in pain
Theory program ■ Ergonomics
■ Benefits of relative rest
■ Diaphragmatic breathing exercises as the basis for
relaxation, body awareness and postural control.
■ Pelvic floor/gyration exercises.
Practical
program
■ Propioceptive and posture awareness exercises.
■ Strengthening exercises of the psoas and the
posterior chain: Paravertebral muscles, gluteus,
ischiotibial muscles.
■ Strengthening exercises of abdominal muscles,
specially the abdominal transversus, gluteus, spinal
extensors and scapular muscles.
Psychologist
4 hours
Objective: Provide participants with cognitive-
behavioural therapy techniques
Theory program ■ Influences of cognitions, emotions and behaviour
in pain
■ Relaxation guidelines and methods
■ Cognitive restructuring (Modulation of negative
thoughts affecting emotions and pain)
■ Use of attention (Increasing attention focus)
Practical
program
■ Assertiveness (improving social relationships)
■ Problem solving (training in step by step
techniques for decision making)
■ Time organization and reinforcement of reform
activities and physical exercise.
■ Life values (increasing concordance between values
and behaviour)
■ Relapse prevention
Notes: GP = general practitioner; LBP = low back pain.
Table 3 Contents of the educational Digital Video Disk
Contents of the educational Digital Video Disk
■ Basics on anatomy and biomechanics of the spine
■ Causes and mechanisms of pain
■ Recommendations on dealing with pain and coping with it in daily
life
■ A series of stretching, strengthening, and flexibility exercises and
methods to promote physical activity
■ Ergonomics applied to daily life (home, work and leisure)
■ Cognitive restructuring (Modulation of negative thoughts affecting
emotions and pain)
■ Use of attention (increasing attention focus)
■ Assertiveness (Improving social relationships)
■ Problem solving (training in step by step techniques for decision
making)
■ Time organization and reinforcement of reform activities and physical
exercise
■ Life values (Increasing concordance between values and behaviour)
■ Relapse prevention
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complementary tests; and costs of pharmacological
treatment and disposable supplies for medical and
emergency services use.
These costs will be assessed in accordance with the
official rates most recently published in the Diari Oficial
de la Generalitat de Catalunya (DOGC) for the public
health service.
Direct non-medical costs will include home help
received as a result of disability related to LBP, patient
time directly related to the intervention (time spent in
transportation, waiting rooms, and the intervention),
non-medical activities (gymnasium, swimming, Yoga/Tai
Chi/stretching), and additional therapies (acupuncture,
osteopathy, massage, homeopathy).
Indirect non-medical costs include loss of productivity
and will be calculated on the basis of time off work
(absenteeism) as well as reduced productivity at the
workplace (presenteeism). The respondent will be asked
to quantify how much work was actually performed dur-
ing regular hours and the quality of this work as com-
pared with a normal work day [42,43].
Costs will be calculated in euros (€) based on the most
actualized prices using the general Spanish consumer
price index.
Table 4 Measurements of cost
Measurements of costs
Type of
cost
Costs for Specification Source of resources used Source of costs per ‘unit’ Cost
calculation
Medical
direct
costs
Primary Health
Care
consultations
General Practitioner
Practice nurse
Physiotherapist
Psychologists
Self-reported and comparison
the answers by E-cap
(electronical clinical records
e-cap)
Catalan Institute of Health
provider
Number of
visits × tariff
Secondary care
consultations
Other specialists Self-reported and comparison
by E-cap
Catalan Institute of Health
provider
Number of
visits × tariff
diagnostic tests Radiology, magnetic resonance,
scanner, electromyogram
Self-reported and comparison
by E-cap
Catalan Institute of Health
provider
Tests done ×
tariff
Pharmaceutical
treatment
muscle relaxants, analgesics,
NSAIDs, corticoids, anxiolytic,
Antidepressants and gastric
protectors
Self-reported and comparison
by E-cap
Standard Pharmaceutical Prices by
Consejo General de Colegios
Oficiales de Farmacéuticos
Medicines
bought ×
price
medicine
Additional
medical
services
Traumatology, rehabilitation,
neurosurgery, other therapies
Self-reported and comparison
by E-cap
Catalan Institute of Health
provider
Services
provided ×
tariff
Material
provided in
intervention
leaflet, booklet, CD, DVD Provider Provider; production costs Number of
material ×
price per
material
Material used
in intervention
mat, postural stool, tennis ball Provider Provider; market price Number of
material ×
price per
material
Non
medical
direct
costs
Aid to patients
who face
disabilities
Aid in household, aid for young
children
Self-reported Patient hours of aid
× price per
aid
Additional
therapies
Gymnasium, swimming, Yoga/Tai
Chi/stretching, other
Self-reported Patient Number of
months ×
price per
month
Acupuncture, osteopathy,
massage, homeopathy, other
therapies
Self-reported Patient Number of
sessions ×
price per
session
Indirect
costs
Cost of lost
productivity
Absenteeism Self-reported and comparison
by E-cap
Self-reported, profession
classification assigned according
to Spanish National Institute of
Statistics
Days of work
sick leave ×
salary
Presenteeism Self-reported Self-reported, profession
classification assigned according
to Spanish National Institute of
Statistics
reduction
percentage ×
productivity
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Data collection and information sources All partici-
pants will be invited to attend the PHCC for outcome
assessments. They will be assessed at the first visit to
the PHCC and at 3 months, 6 months, and 12 months
after the onset of LBP. Primary data will be collected
from the patient by an interview and the electronic clin-
ical records. All outcomes will be measured at the indi-
vidual level.
The data source of the costs of lost productivity and
indirect costs of wages lost to LBP, whether remunerated
or not, will be Spain’s National Statistics Institute (INE)
[44-46], calculated on the basis of the national classifica-
tion of economic activity [45]. Each participant’s profes-
sion will be placed into one of the categories of economic
activity.
A human capital focus will be used to determine the
cost of absenteeism from paid employment. This mea-
sure considers the social value of an individual to equal
future potential production, measured by the value of
anticipated lifetime income. A limitation of this method
is it does not take unemployment into account (retirees
or those with a disability), although we will correct for
this by assigning a value equal to the minimum wage or
average salary of their profession [46,47].
Sample size The sample-size calculation is based on
change in RDQ at 3 months after onset of LBP. It is
recommended that a change of 2 to 3 points on the RDQ
should be considered the minimum clinically important
change [48]. To allow for the cluster randomisation by
PHCC, we assume an intraclass correlation coefficient of
0.1 [49] and a minimum average number of individuals
sampled per PHCC of 25. In order to detect a difference
of 2.5 points between the two intervention arms with a
standard deviation of 5.7 [48,50], an alpha error of 0.05, a
beta error of 0.10, and a 20% dropout rate, a sample size
of 932 subjects was required, 466 subjects per interven-
tion arm. Therefore, the total number of PHCCs is 38
(19 in each group).
Statistical Analysis The effectiveness of the interven-
tion will be analysed in accordance with CONSORT
guidelines, extended to a cluster randomised trial. The
analysis will be carried out according to the intention-
to-treat principle. Cost, outcomes and use of resources
will be reported as mean values with standard deviations
for each intervention arm. Comparisons will be done
between arms on characteristics of the study population.
Mean differences between groups in cost, outcomes and
resources, and 95% confidence intervals were calculated.
If cost data do not conform to the assumptions for stan-
dard statistical tests, the non-parametric bootstrap
method will be performed [51].
To address potential biases due to incomplete follow-
up, we will analyse patients with complete data at all
time points and those with data at any time point, using
the multiple imputation approaches to replace missing
values. Bias due to non-response will be assessed at
each follow-up.
The temporal horizon of the study is 3 months
because this is the time of change to a chronic stage
and 12 months to evaluate the outcomes at long term.
The discount rate will be 3% [52] that is closest to the
actual discount rate.
To establish an important change in individuals, we will
contrast the distributions of changes in all the question-
naires and in each assessment, in individuals who change
to chronic state and those who do not [48]. We will do the
same between those individuals who return to work and
those who do not. We will compare individual change
scores to the standard error of measurement (SEM).
To detect changes in groups, the intervention effect
will be calculated through the effect size for each ques-
tionnaire and at each assessment. Effect size will be cal-
culated following the method of Kazis et al [53].
We will evaluate responsiveness of each scale by stan-
dardized response mean (SRM) [54] and receiver-operat-
ing characteristic method (ROC curve). Since the unit of
randomisation is the PHCC, we will use a regression
analysis of individual level data using methods for clus-
tered data [55].
To adjust comparisons and to account for cluster ran-
domisation, multilevel linear regression analyses on
repeated measures on each of the outcome scales will
be used to assess the effect of intervention and to inves-
tigate the factors that influence each of the outcome
scales at each time point. The possible association
between intervention and time will be studied. The
PHCC and the individual will be considered as random
effects and intervention and time as fixed effects.
The incremental cost-effectiveness ratios were calcu-
lated as the difference in mean costs between the
MBEGI and the usual care divided by the difference in
mean effect, measured in natural unit, between MBEGI
and the usual care.
Utilities will be calculated from the SF-12 scores with
the corresponding Oxford University algorithm. The
QALY will be calculated using these utilities, adjusted
by time. The incremental cost-utility ratio will be calcu-
lated by dividing the difference in mean total costs
between the MBEGI and the usual care by the difference
in QALYs [56,57].
To determine the uncertainty surrounding these
ratios, 95% confidence intervals for cost-effectiveness
ratios will be calculated by the non-parametric bootstrap
method [51].
Acceptability curves will be use to determine the
probability that the MBEGI will be cost effective com-
pared with usual clinical care at different values of the
maximum acceptable ratio.
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A deterministic sensitivity analysis will be performed to
assess the robustness of the results [58]. The sickness days,
GP visits and the number of medications will be measured
to assess the impact on costs and cost-effectiveness. The
discount rate will be 1% and 5%.
Confidence intervals around point estimates will be
reported. The results will be presented in a disaggre-
gated as well as aggregated form.
The significance level of all models will be set at 5%.
The SPSS statistical package for Windows, version 19
(SPSS Inc., Chicago, IL) and the Stata/SE version 11·1
for Windows (StataCorp LP) will be used for statistical
analysis.
Ethical aspects The study will be conducted according
to Guidelines of the Helsinki Declaration and of Good
Clinical Research Practice. The project/study protocol
has been approved by the Ethical and Clinical Research
Committee of IDIAP Jordi Gol, Institute of Research in
Primary Health Care.
This trial is registered as Current Controlled Trials
(ISRCTN58719694)
More details of the intervention, of patient adherence
to the intervention and to non-pharmacological treat-
ment, and the analysis of effectiveness have been pub-
lished in the protocol for analysis of the effectiveness of
the intervention [21].
Discussion
With this study, we hope to contribute evidence about the
cost-effectiveness and cost-utility of MBEGI in reducing
episodes of non-specific LBP and the associated social and
health costs. This evidence could help health professionals
and administrators to make more efficient decisions to
address this problem in the primary care setting.
A review of the literature found very few studies of
cost-effectiveness and cost-utility related to LBP, and
that considered the societal perspective and used a rigor-
ous methodology and a broad sample [59]. On the other
hand, the recent review by Catalá-López et al. points out
the lack of economic assessment in Spain with respect to
musculoskeletal care [60]. The cost-effectiveness and
cost-utility analysis of MBEGI proposed in this study,
which incorporates most of the relevant costs of LBP,
includes a follow-up period that will permit the identifi-
cation of significant changes and the systematic descrip-
tion of the methods used, will facilitate the interpretation
and comparison of the results.
A strength of the study is that the MBEGI has been
designed as a pragmatic effectiveness trial. In this type
of design, the interventions reflect what may happen in
practice and the results are often more generalizable
and hence preferable for economic evaluation [44,61].
Information about consumption of resources will be
gathered in parallel with the collection of data about the
effectiveness of the intervention; therefore, primary data
will be obtained in terms of effectiveness and costs to
inform the economic evaluation.
The analysis will adopt the social perspective; it is unu-
sual to encounter economic evaluation studies with this
perspective, even though LBP is a disease with an impor-
tant impact on the daily life of the patient as well as the
society. Nonetheless, the determination and collection of
all of the costs and benefits to the patient, family mem-
bers, and the National Health Service is a complex task.
This study attempts to include the majority of all costs
analysed in the studies reviewed. Nonetheless, some costs
have been eliminated, such as those attributable to the pri-
mary care centre operations, since we could assume that
there will be no relevant differences between the treatment
and control group in this regard.
It is worth highlighting the inclusion of the concept of
presenteeism in estimating labour costs. This concept
has not often been applied in calculating the costs of
LBP, and seems to have an important impact on those
costs [15,62].
The fact that the direct costs of health care will be
obtained from the most recent information published in
the DOGC will mean that their allocation will be
standardized.
We should also note that the participants will be are
being recruited from PHCC. Although this aspect could
affect the external validity of the study, the National
Health Service in Spain provides universal free coverage.
More than 70% of the general population visits a primary
care centre at least once a year and this percentage
increases if we consider longer time periods. In addition,
given the size and heterogeneity of the sample and the
high number of participating centres, we can assume that
the study population represents the Spanish population
with this problem, and therefore the results are potentially
generalizable.
On the other hand, we have assumed that the usual
care attention is to a certain extent homogeneous among
the participating GP and nurses. Most of these profes-
sionals work for the Catalan Institute of Health and fol-
low the recommendations of the “Clinical Practice
Guidelines for lumbar column pathology in adults”.
Nonetheless, it is very probable that a certain variability
exists in their application. In addition, the professionals
who participate in research projects tend to be both
motivated and more experienced. In any case, we assume
that there may be variability, even though this would be
similar in both arms of the study.
Another possible limitation is subjects lost to follow-
up and/or the non-compliance rate, due to the long
duration of the fieldwork. Efforts will be made to mini-
mize these losses with the use of reminders (telephone
calls, text messages, and the 6-month interview) that
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facilitate follow-up and compliance, along with the
empathy and communication skills of the interviewers
who will be doing the fieldwork.
Despite the 1-year time horizon, our study includes
data from more than a natural year, so the possible effect
of inflation could slightly modify the prices and values of
the different variables. To minimise these effects, we will
convert costs and benefits obtained in different years to a
base year: the year with the most recently published price
levels. In addition, a 3% rate will be applied, which is clo-
sest to the actual discount rate.
Another point to consider in the costs estimation is
the possible influence of the current economic situation.
A review by Degenais et al. [17] showed that the major
part of costs derived from LBP are indirect, resulting
from the sick leave factor, which has a very important
weight in the equation. In addition, due to the current
labour uncertainty in our context, workers are more
hesitant to request sick leave, which could contribute to
underestimation of costs. We will attempt to minimise
this impact by including the concept of workforce pre-
senteeism and by the sensitivity analysis.
We also cannot discard the possible effect on costs
estimation of the high unemployment rates related to
the current economic crisis. Nonetheless, it can be
assumed that the level of unemployment would be simi-
lar in both study groups, which then would not affect
the cost-utility and cost-effectiveness results.
If the intervention is shown to be cost-effective and
utility-cost, it could be applied to the primary care
population with the expectation of the following results:
■ decreased intensity of LBP
■ decreased duration of the episode and recurrent
LBP
■ improved quality of life
■ decreased incidence of chronic LBP
■ decreased days of labour absenteeism and
presenteeism
■ reduced pharmacy costs
■ reduced costs to the National Health System in
the provision of services due to this pathology
■ Reduced social costs to the patient and his/her
family
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